KR101913135B1 - 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체 - Google Patents

감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체 Download PDF

Info

Publication number
KR101913135B1
KR101913135B1 KR1020147003465A KR20147003465A KR101913135B1 KR 101913135 B1 KR101913135 B1 KR 101913135B1 KR 1020147003465 A KR1020147003465 A KR 1020147003465A KR 20147003465 A KR20147003465 A KR 20147003465A KR 101913135 B1 KR101913135 B1 KR 101913135B1
Authority
KR
South Korea
Prior art keywords
formula
alkyl
group
alkyloxy
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147003465A
Other languages
English (en)
Korean (ko)
Other versions
KR20140063595A (ko
Inventor
가렛트 베를론트 미네
프랑수아 파울 비쇼프
헨리쿠스 야코부스 마리아 기즈센
아드리아나 인그리드 벨터
세르게 마리아 알로이시우스 피터스
디디에 쟝-클로드 베르텔로
Original Assignee
얀센 파마슈티칼즈, 인코포레이티드
셀좀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티칼즈, 인코포레이티드, 셀좀 리미티드 filed Critical 얀센 파마슈티칼즈, 인코포레이티드
Publication of KR20140063595A publication Critical patent/KR20140063595A/ko
Application granted granted Critical
Publication of KR101913135B1 publication Critical patent/KR101913135B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
KR1020147003465A 2011-07-15 2012-07-12 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체 Expired - Fee Related KR101913135B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11174120.3 2011-07-15
EP11174120 2011-07-15
PCT/EP2012/063667 WO2013010904A1 (en) 2011-07-15 2012-07-12 Novel substituted indole derivatives as gamma secretase modulators

Publications (2)

Publication Number Publication Date
KR20140063595A KR20140063595A (ko) 2014-05-27
KR101913135B1 true KR101913135B1 (ko) 2018-10-30

Family

ID=46506432

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147003465A Expired - Fee Related KR101913135B1 (ko) 2011-07-15 2012-07-12 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체

Country Status (16)

Country Link
US (1) US9115143B2 (https=)
EP (1) EP2731948B1 (https=)
JP (1) JP6068464B2 (https=)
KR (1) KR101913135B1 (https=)
CN (1) CN103874702B (https=)
AR (1) AR087182A1 (https=)
AU (1) AU2012285931B2 (https=)
BR (1) BR112014000713A2 (https=)
CA (1) CA2841102C (https=)
EA (1) EA023045B1 (https=)
ES (1) ES2555167T3 (https=)
IL (1) IL230422B (https=)
IN (1) IN2014MN00258A (https=)
MX (1) MX2014000626A (https=)
TW (1) TWI567079B (https=)
WO (1) WO2013010904A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
AU2010262036B2 (en) 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
KR101913135B1 (ko) 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
US9181245B2 (en) 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
CA2891755C (en) 2013-01-17 2021-10-26 Janssen Pharmaceutica Nv Substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
BR112019001270A2 (pt) 2016-07-30 2019-04-30 Bristol-Myers Squibb Company compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
KR102688509B1 (ko) 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
PE20211246A1 (es) 2017-10-11 2021-07-13 Hoffmann La Roche Compuestos biciclicos para su uso como inhibidores de rip1 quinasa
JP7265554B2 (ja) 2017-11-14 2023-04-26 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール化合物
KR102781141B1 (ko) 2017-12-15 2025-03-13 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 에테르 화합물
EA202091484A1 (ru) 2017-12-18 2021-03-25 Бристол-Маерс Сквибб Компани 4-азаиндольные соединения
JP7304352B2 (ja) 2017-12-19 2023-07-06 ブリストル－マイヤーズ スクイブ カンパニー ６－アザインドール化合物
MX2020005462A (es) 2017-12-19 2020-09-07 Bristol Myers Squibb Co Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EP3728218B1 (en) 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
DK3846903T3 (da) * 2018-09-03 2024-01-02 Hoffmann La Roche Bicykliske heteroarylderivater
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
CN117946116A (zh) 2018-12-13 2024-04-30 豪夫迈·罗氏有限公司 6,7-二氢-5h-吡咯并[1,2-b][1,2,4]三唑-2-胺衍生物
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
EP4041730A1 (en) 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010098495A1 (en) 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Imidazolylpyrazine derivatives
WO2010114971A1 (en) * 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2010126745A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126636T3 (es) * 1992-05-19 1999-04-01 Adir Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
DE60012742T2 (de) 1999-06-10 2005-01-13 Warner-Lambert Co. Llc Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
AU2004215679A1 (en) 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
WO2005016892A1 (en) 2003-08-14 2005-02-24 F. Hoffmann-La Roche Ag Gabanergic modulators
JP2007527904A (ja) 2004-03-08 2007-10-04 プロシディオン・リミテッド グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
CA2580119A1 (en) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
ES2400287T3 (es) 2005-03-14 2013-04-08 High Point Pharmaceuticals, Llc Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006293635A1 (en) 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as CCR3 receptor liquids
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
JP4987873B2 (ja) 2005-10-11 2012-07-25 ケムチュア コーポレイション 二芳香族アミン
TW200804386A (en) 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
JP2010511019A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物
CN101631779A (zh) 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme piperidine
AU2008248129B8 (en) 2007-05-07 2013-05-30 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2155740B1 (en) 2007-05-11 2011-01-26 F. Hoffmann-La Roche AG Hetarylanilines as modulators for amyloid beta
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
CL2008001914A1 (es) 2007-06-29 2009-07-17 Schering Corp Compuestos heterociclicos de nitrogeno y oxigeno,moduladores de gama secretasa, composicion farmaceutica de dichos compuestos; kit farmaceutico y su uso para prevenir o tratar enfermedades asociadas al sistema nervioso central como alzheimer, sindrome de down, enfermedades neurodegenerativas, inhibir el deposito de proteina amiloide.
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
WO2009032277A1 (en) 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
US8450343B2 (en) * 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
MX2010008700A (es) 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
EP2356115A1 (en) 2008-11-06 2011-08-17 Schering Corporation Gamma secretase modulators
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
WO2010065310A1 (en) 2008-12-03 2010-06-10 Via Pharmaceuticals, Inc Inhibitors of diacylglycerol acyltransferase
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
WO2010098487A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
US20120053165A1 (en) 2009-03-03 2012-03-01 Pfizer Inc. Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
JPWO2010106745A1 (ja) 2009-03-16 2012-09-20 パナソニック株式会社 アプリケーション実行装置
AU2010262036B2 (en) 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
TW201307347A (zh) * 2010-11-01 2013-02-16 Arqule Inc 經取代苯並－咪唑並－吡啶並－二氮呯化合物
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
KR101913135B1 (ko) 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010098495A1 (en) 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Imidazolylpyrazine derivatives
WO2010114971A1 (en) * 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2010126745A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS

Also Published As

Publication number Publication date
EA201490287A1 (ru) 2014-05-30
JP6068464B2 (ja) 2017-01-25
US9115143B2 (en) 2015-08-25
KR20140063595A (ko) 2014-05-27
WO2013010904A1 (en) 2013-01-24
BR112014000713A2 (pt) 2017-01-10
TW201315736A (zh) 2013-04-16
ES2555167T3 (es) 2015-12-29
AU2012285931B2 (en) 2017-01-12
CN103874702A (zh) 2014-06-18
IL230422B (en) 2018-03-29
JP2014518286A (ja) 2014-07-28
CA2841102C (en) 2019-08-13
CN103874702B (zh) 2015-12-09
MX2014000626A (es) 2014-04-30
EP2731948A1 (en) 2014-05-21
NZ619683A (en) 2015-01-30
EA023045B1 (ru) 2016-04-29
US20140148450A1 (en) 2014-05-29
CA2841102A1 (en) 2013-01-24
AR087182A1 (es) 2014-02-26
TWI567079B (zh) 2017-01-21
EP2731948B1 (en) 2015-09-09
IN2014MN00258A (https=) 2015-09-25

Similar Documents

Publication Publication Date Title
KR101913135B1 (ko) 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
JP6987937B2 (ja) Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
JP5576403B2 (ja) γ分泌酵素調節物質としての新規置換二環複素環化合物
AU2015233654B2 (en) Heteroaryl Syk inhibitors
KR101410453B1 (ko) 소정의 화학 물질, 조성물 및 방법
KR20190012167A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
KR20120123677A (ko) 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 트리아졸 유도체
KR20150009548A (ko) (무엇보다도) 알츠하이머병의 치료에 유용한 치환 3,4-디하이드로-2h-피리도[1,2-a]피라진-1,6-디온 유도체
JPWO2015012328A1 (ja) 複素環化合物
TW201609726A (zh) 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN102256974A (zh) 作为γ分泌酶调节剂的取代的二环咪唑衍生物
CN119654315A (zh) 作为qpctl和qpct抑制剂用于治疗癌症的3-(6-吡啶-3-基)-2-[4-(4-甲基-4h-1,2,4-三唑-3-基)哌啶-1-基]苯甲腈衍生物和类似化合物
KR102171710B1 (ko) 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
WO2022194779A1 (en) Heterocyclic derivatives as janus kinase inhibitors
CN116981459A (zh) 作为詹纳斯激酶抑制剂的杂环衍生物
HK40123924A (zh) 作为qpctl和qpct抑制剂用於治疗癌症的3-(6-吡啶-3-基)-2-[4-(4-甲基-4h-1，2，4-三唑-3-基)哌啶-1-基]苯甲腈衍生物和类似化合物
MX2010011136A (es) Derivados de pirrolo [2,3-d] pirimidin-2-il-amina como inhibidores pkc-theta.
NZ619683B2 (en) Novel substituted indole derivatives as gamma secretase modulators
HK1178163A (en) Novel substituted bicyclic triazole derivatives as gamma secretase modulators
HK1163683A (en) Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
HK1161241A (en) Substituted bicyclic imidazole derivatives as gamma secretase modulators
HK1169113A (en) Substituted triazole and imidazole derivatives as gamma secretase modulators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20211005

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221025

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221025